If you have been reading about Preclinical research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-21. Numbers and descriptions here follow the published literature rather than marketing material.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
== Structure == C1q is a 460 kDa protein formed from 18 peptide chains in 3 subunits of 6. Each 6 peptide subunit consists of a Y-shaped pair of triple peptide helices joined at the stem and ending in a globular non-helical head. The 80-amino acid helical component of each triple peptide contain many Gly-X-Y sequences, where X and Y are proline, isoleucine, or hydroxylysine; they, therefore, strongly resemble collagen fibrils.
Depending on the experimental conditions, cycloaddition of acetone and ketene produces either β-isovalerolactone or 4,4-dimethyloxetan-2-one, both of which hydrolyze under basic conditions to yield the conjugate base of HMB. The haloform reaction provides another pathway to HMB involving the exhaustive halogenation of the methyl-ketone region of diacetone alcohol with sodium hypobromite or sodium hypochlorite; Diacetone alcohol is readily available from the aldol condensation of acetone. An organometallic approach to HMB involves the carboxylation of tert-butyl alcohol with carbon monoxide and Fenton's reagent (hydrogen peroxide and ferrous iron). Alternatively, HMB can be prepared through microbial oxidation of β-methylbutyric acid by the fungus Galactomyces reessii.
==== List of P-CABs in the markets (First year of approval for clinical use) ==== Revaprazan (2006) Vonoprazan (2014) Tegoprazan (2018) Fexuprazan (2021) Keverprazan (2023/China) Zastaprazan (2024/South Korea)
Sources: en.wikipedia.org
=== Opioid overdose and/or opioid use disorder === Methocinnamox is able to reverse the respiratory depressant effects of fentanyl and heroin in animals. However, unlike naloxone, another opioid antagonist, its action lasts around 2 weeks if administered subcutaneously and up to 5 days if administered intravenously. This could make it a better antidote than naloxone in opioid overdoses, because naloxone usually lasts around 30 minutes, there is a need for repeated administration and a danger of renarcotization. By acting longer, methocinnamox prevents these dangers. Methocinnamox has not yet been tested in humans as of 2022. However, it has been tested in rodents and monkeys. It was reported in March 2020 that clinical trials of methocinnamox were expected to begin within 18 to 24 months. In March 2023, it was reported that a phase 1 clinical trial of methocinnamox funded by the National Institutes of Health (NIH) would possibly start in 2024.
=== Mechanism of action === Sabizabulin, as an orally available molecule, acts on microtubules, a component of the cytoskeleton. It binds to the colchicine binding site on the beta subunit of tubulin, as well as a novel site on the alpha subunit, and causes both to crosslink, thus depolymerizing microtubules and preventing their polymerization. By preventing mitotic spindle formation, this directly inhibits mitosis of tumor cells and endothelial cells attempting to form new blood vessels to feed them. In parallel, microtubule-mediated trafficking of cellular components (including androgen receptors into the nucleus), thus, a potential anti-androgen agent. The transport of viral particles (including SARS-CoV-2) may also be inhibited. These activities can inhibit viral replication and assembly. Inhibition of tubulin polymerization can also inhibit the release of pro-inflammatory cytokines and disrupt the activities of inflammatory cells.
=== Metabolic managements === Though metabolic dysfunction is common among CAIS individuals, there is no standard treatment. Clinical management relies heavily on symptomatic therapies. Regular monitoring of bone mineral density (BMD), blood glucose, and lipid profile is recommended. Besides HRT, supplementation with calcium and vitamin D should be considered in patients with reduced BMD. Bisphosphonates may be considered in patients with severe osteoporosis and/or fractures. For individuals with obesity, insulin resistance, or glucose dysregulation, metformin is the first-line therapy for improving insulin sensitivity and glycemic control. GLP-1RAs such as liraglutide and semaglutide may be efficacy and SGLT-2 inhibitors also hold promise for CAIS individuals with obesity or type 2 diabetes. Personalized advice on diet and exercise may be helpful as well.
Sources: en.wikipedia.org
In 1958, HVEC established High Voltage Engineering Europa (HVEE) in Amersfoort, Netherlands to supply accelerators to the European common market. The subsidiary was created in response to demand for accelerators in the European common market and export-controlled markets. HVEE manufactured HVEC's lower-voltage Van de Graaff accelerators for industries in the European common market, as well as insulated-core transformer power supplies for low-voltage electron beams. According to production records compiled through 2004, HVEE manufactured 93 accelerators across various voltage ranges, mostly in the 0.5–2 MV range. HVEE also produced smaller numbers of higher-voltage systems, including three accelerators in the 5–7 MV range and one in the 4-5 MV range. High Voltage Engineering Europa continued operations after its parent company's bankruptcy. HVEE produced low-voltage 1–5 MV, solid-state voltage generators with the trade names Tandetron and Singletron, originally designed by the General Ionix Corporation in Massachusetts. Having shifted away from belt-charged accelerators, HVEE's lower voltage accelerators now incorporate newer charging technologies.
== Legislative and regulatory matters == Traceability of food is legally required in the European Union (Regulation 178/2002) with dedicated initiatives in EU countries and the UK and Northern Ireland. In the EU, under the renewed Sustainable Product Policy Initiative, the inclusion of a Digital Product Passport has been proposed. The EU sustainable product policy was renewed in function of the European Green Deal and the new Circular Economy Action Plan. and revises the Ecodesign Directive. As such, similarly to material passports, it intents to assist the circular economy. In the United States, various government agencies have oversight or regulatory control over different aspects of fresh fruit and produce production, processing and distribution. These include the U.S. Department of Agriculture, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control. Some groups have pushed for a single food-safety agency, on-farm improvements and improved reporting and surveillance of foodborne illness outbreaks. The draft Food Safety Enhancement Act of 2009 was introduced May 27, 2009, in the U.S. House of Representatives. It would expand FDA authority, require registration of food manufacturers and processors, regulate crop cultivation and harvesting and other measures. After committee hearings and extensive amendment, the bill (HR2749) passed the House on July 30, 2009. HR2749 does not specifically endorse the PTI, or prescribe a traceability method or methodology, but instead Section 107 calls for regulations establishing a tracing system that includes:
== Long Range Patrol – Improved == While the MRE was lighter than the canned MCI and had more dietary energy than the LRP ration, it had certain problems. US Special Operations forces found it too bulky, and troops on maneuvers found some menu items were unsuited for easy digestion in cold-weather, high-altitude, high-temperature, or humid environments. While unofficial practice was to strip out items deemed "unnecessary", this also reduced the ration's dietary energy content. Faced with these problems, this forced the adoption of a specialized ration for light troops or commando units on extended field operations. In 1994, a new version of the LRP called the Food Packet, Long-Range Patrol – Improved (LRP-I) was created. It was an 11-ounce (310 g) ration that came in a brown plastic retort pouch that allowed the user to reconstitute and cook the ration directly in the pouch. This was an improvement over the earlier LRP packet, which had to be boiled or soaked in a canteen cup or other cookware.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.